AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer

Lynparza bottle
The Lynparza-Avastin duo slashed the risk of disease progression or death by 41% in a phase 3 trial of ovarian cancer patients who had responded to their first round of chemo. (AstraZeneca)

AstraZeneca and Merck are racing against GlaxoSmithKline to snag an expanded nod for Lynparza in ovarian cancer patients who responded to their first round of chemo. And the partners just got a boost from the FDA.

The agency bestowed its priority review status on a combination of Lynparza and Roche’s Avastin, setting the duo up for an approval in first-line patients—with or without BRCA mutations—next quarter, the companies said Monday.

RELATED: ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

Regulators based their decision on data from the Phase 3 Paola-1 trial, presented at the European Society for Medical Oncology (ESMO) annual meeting in September, which showed the Lynparza-Avastin tandem could slash the risk of disease progression or death by 41% in patients with or without BRCA mutations.

Lynparza-Avastin patients across the board went a median 22.1 months without seeing their disease worsen, an advantage of more than six months over the Avastin-placebo arm.

What “every woman wants to know is, ‘how long will I benefit from this therapy?’ To be able to say at the median, it was nearly two years, that is a milestone we haven’t been able to achieve before,” Dave Fredrickson, executive vice president and global head of AstraZeneca’s oncology business unit, said at the time.

If Merck and AZ can score a nod for the Lynparza-Avastin pairing, it’ll be their second for Lynparza in the first-line ovarian cancer maintenance setting. Just over a year ago, the therapy grabbed a solo OK for women with BRCA mutations, cueing talk from analysts of a billion-dollar sales boost. Overall, the Avastin combo nod would be Lynparza’s fourth ovarian cancer approval.

RELATED: ESMO: Glaxo sizes up AZ, Merck challenge with Zejula's all-comers ovarian cancer win

But GlaxoSmithKline, which entered the PARP inhibitor field last January with its $5.1 billion Tesaro buyout, isn’t prepared to let AZ and Merck run the show. It unveiled its own positive data at ESMO from a first-line maintenance trial of Zejula, showing the drug could cut the risk of disease progression or death by 38%—without the addition of an additional drug and the toxicities that come along with it.

Suggested Articles

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.